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INTRODUCTION 
 
  
INTRODUCTION:  
Atrial fibrillation is the commonest sustained disorder of cardiac 
rhythm. When it is present many prognostic and therapeutic implications 
exist as overall morbidity and mortality increase appreciably. Despite this, 
atrial fibrillation is sometimes regarded as a fairly trivial and unimportant 
disorder and is often neglected, probably because many patients have few 
symptoms. In fact, some patients with chronic atrial fibrillation may 
require long term treatment with potent antiarrhythmic and anticoagulant 
drugs, which may have important pharmacological interactions and 
adverse effects. In addition, treatment differs importantly for chronic and 
paroxysmal atrial fibrillation and for atrial fibrillation, atrial flutter, and 
the other supraventricular arrhythmias.  
Atrial fibrillation is encountered in many clinical settings. It may, 
for example, be discovered incidentally in an asymptomatic patient, 
develop in a patient who merely has a chest infection, or be found in a 
patient with a ventricular rate of 200 beats/min who is too light-headed to 
stand up. Patients admitted with atrial fibrillation may have many cardio 
respiratory symptoms and clinical features, including syncope and stroke.  
Atrial fibrillation is common in the community, affecting up to 5% of 
people aged 75 or over. It is a major reason for emergency admissions 
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and cause of cardiovascular deaths. Thus most clinicians in hospital and 
general practice will participate in managing such patients. As the 
prevalence of the condition increases with age, atrial fibrillation will 
become increasingly common in the increasingly aging population.  
Atrial fibrillation appears to be more in WHITES than in 
BLACKS.  Blacks have less than half the age adjusted risk of developing 
AF than is seen in whites. 
Epidemiological studies have shown that atrial fibrillation is fairly 
uncommon in people aged under 50 years but is found in 0.5% of people 
aged 50-59, increasing to 8.8% at age 80-89. Furthermore, the arrhythmia 
may be either chronic or paroxysmal. In the Framingham study, 
hypertension, cardiac failure, and rheumatic heart disease were the 
commonest precursors of atrial fibrillation. Up to a third of patients with 
atrial fibrillation, however, may have idiopathic or "lone" atrial 
fibrillation, where no precipitating cause can be identified and no 
evidence of structural heart disease exists. 
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AIM OF THE STUDY 
1) Analysis of etiological features of atrial fibrillation. 
2) Analysis of clinical features of atrial fibrillation.  
3) Analysis of Complications of atrial fibrillation. 
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REVIEW OF LITERATURE 
 
  
REVIEW OF LITERATURE 
HISTORY OF ATRIAL FIBRILLATION: [1, 2, 3, 4, 5] 
 For two centuries after Harvey the atrial pulse was often regarded 
as independent of the heart beat. This misunderstanding was mainly 
because of the frequent failure of the irregular heart to elicit a radial 
pulse: the "pulse deficit" of later times. Harvey observed ineffective 
palpitation of the atrium just before death. This was probably atrial 
fibrillation. He established the origin of the heart beat in the right atrium. 
Harvey's observations were confirmed and extended by de Senac in the 
mid-eighteenth century. He correlated gross irregularities (palpitation) 
with necropsy observation of mitralvalve disease and dilatation of the left 
ventricle. He emphasised the origin of the heart's irregularity from the 
distended atrium consequent on distension or reflux of blood irritating the 
atrial wall. He also commented on disconcerted action and rippling of the 
ventricular wall before final cessation of movement in a dying heart 
(ventricular fibrillation). De Senac's ideas were a century and a half ahead 
of his time.  
                In clinical practice and with the aid of Laennec's recently 
invented stethoscope, Robert Adams reported in 1827 the association of 
irregular pulses with mitral stenosis; in 1863, Etienne Marey published a 
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pulse tracing from such a patient. Other early descriptions of atrial 
fibrillation and its importance were published early this century by Sir 
James Mackenzie and Heinrich Haring.  
             The discovery of the therapeutic properties of digitalis leaf 
(Digitalis purpurea) in 1785 by William Withering brought some relief to 
patients with severe heart failure. It is interesting that Withering recorded 
a patient who had a weak, irregular pulse that became "more full and 
more regular" after five draughts containing Fol Digital Purp oz iv. In 
1935 Jean Baptiste Bouilland said that he considered digitalis to be "a sort 
of opium for the heart." 
                The main diagnostic breakthrough was the invention of the 
electrocardiograph by William Einthoven in 1900. A close friend of 
Einthoven, Sir Thomas Lewis at University College Hospital, London, 
was the first to record an electrocardiogram in a patient with atrial 
fibrillation. (1995) 
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DEFINITION:  [6] 
 
                Atrial fibrillation is an arrhythmia that is characterised by 
seemingly disorganised and depolarization without effective atrial 
contraction. 
 
                    During atrial fibrillation electrical activity of atrium can be 
detected on ECG as small irregular baseline undulation of variable 
amplitude and morphology called ‘f’ waves, at a rate of 350 to 600 
beats/min   
 
PREVALENCE: [7] 
 
            Overall prevalence of 0.5% in adult population of UK. The 
prevalence raises with age affecting 2-5% of 70 yrs olds and 9% of those 
aged over 80 yrs. 
 
FRAMINGHAM DATA: 
 
           Atrial fibrillation found in 1% of persons older than 60 yrs to more 
than 5% of patients older than 69 yrs .The over all chance of atrial 
fibrillation developing over a period of 2 decades in patients older than 30 
yrs . Estimates are that 2.5 million Americans have atrial fibrillation. [6] 
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CLASSIFICATION OF ATRIALL FIBRILLATION: 
 
1. PAROXYSMAL—Intermittent self terminating episodes [7] 
Duration less than 7 days with spontaneous termination [8] 
 
2.PERSISTENT—  
Prolonged episodes terminated by electrical or chemical Cardio version.  
Duration greater than 7days [8] 
 
3.PERMANENT:  
Present all the time [9] Restoring sinus rhythm is either not possible or is 
not deemed appropriate.                           
 
4.LONE ATRIALL FIBRILLATION 
AF in the absence of clinical or echocardiography findings of 
cardiopulmonary disease patients with LAF who are under 65 have best 
prognosis. 
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According to, American heart association, American college of 
cardiology and European society of cardiology have proposed the 
following classification system based on simplicity and clinical 
relevance: 
 
1     FIRST DETECTED AYTRIAL FIBRILLATION: 
 
                    Any patient newly diagnoses with atrial fibrillation fits in 
this category as the exact onset and chronicity of disease is often 
undertaken. 
 
2. RECURRENT ATRIAL FIBRILLATION: 
                       Any patient with 2 or more identified episodes of AF is 
called recurrent AF. It is classified into paroxysmal and persistent. 
 
o Paroxysmal—terminates spontaneously within 7 days most 
commonly within 24 hrs.            
 
o Persistent or chronic AF—AF established for more than 7 
days. 
 
3. LONE AF (LAF) [6,7] 
8
  
     
GENETICS OF FAMILIAL ATRIAL FIBRILLATION: [10] 
             Mutations in the KCNQ1 , KCNE2 and KCNJ2   gene cause 
familial atrial fibrillation. In heart (cardiac) muscle, the ion channels 
produced from the KCNE2, KCNJ2, and KCNQ1 genes play critical roles 
in maintaining the heart's normal rhythm. Mutations in these genes have 
been identified in only a few families worldwide. These mutations 
increase the activity of the channels, which changes the flow of potassium 
ions between cells.  
Familial atrial fibrillation inherited in autosomal dominant pattern. 
PATHOPHYSIOLOGY: [11] 
3 mechanism 
1. Enhanced automaticity in the LA extending to proximal 5-6cm 
portion of pulmonary veins. 
2. Electrical remodelling of the atria with resultant shortening of 
atrial refractory period increases the duration and stability of AF 
          (Atrial fibrillation begets atrial fibrillation) 
3. In chronic AF, areas of functional conduction block further 
divide and maintain persistently chronic electrical state. 
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I. ATRIAL FACTORS: 
1. Atrial fibrosis: 
 
  The most frequent pathoanatomic changes in AF are atrial fibrosis 
and loss of atrial muscle mass. 
 
  Histologically shows – patchy fibrosis, juxtaposed with normal 
atrial fibrosis which may account for non homogeneity of conduction. 
 
  The SA and AV nodes may also be involved accounting for SICK 
SINUS SYNDROME and AV block. 
 
Biopsy from LA post well revealed  
 
Mild to moderate fibrosis in AF of short duration, severe fibrosis 
and loss of    muscle mass in long standing AF.  
 
Genetic diseases like lamin AC gene mutation play a role in atrial 
fibrosis. 
 
Other trigger fibrosis includes inflammation as seen in 
sarcoidosis and auto immune disorders. 
10
  
 
2. Amyloidosis 
3. Hemochromatosis 
4. Endomyocardial fibrosis 
5. Atrial dilatation 
   This triggers the atrial fibrosis. 
 
      Atrial dilatation in any type of heart disease includes systemic 
Hypertension, Heart failure, valvular heart disease, CAHD. In this 
conditions stretch activates several molecular pathways, including renin 
angiotensin aldosterone system, Angiotensin II and transforming growth 
factor –B1 are unregulated in response to stretch and these molecules 
induce production of connective tissue growth factors. 
 
        ACE and angiotensin II receptor blockade had potential to 
prevent AF by reducing fibrosis. 
 
 ATRIAL MECHANISM: 
 
1. Automatic focus theory: 
In which the arrhythmia persist only in isolated regions of atrial 
myocardium. 
11 
  
 
This theory received minimal attention until the important 
observation that a focal source for AF could be identified in humans and 
ablation of this source could extinguish AF. While pulmonary veins are 
the most frequent source of these rapidly atrial impulses, foci have also 
been found in the superior venacava, ligament of Marshall, left 
posterior free wall, christa terminalis, coronary sinus. 
 
 2. Multiple –wavelet hypothesis:  
The multiple wavelet hypothesis as the mechanism of re-entrant 
AF was advanced by more colleagues who proposed that fractionation of 
wave fronts propagating through the atria results in self perpetuating 
“daughter wavelets” The number of wavelets at anytime depends on 
refractory period, mass conduction velocity in different part of atria. 
 
A large atrial mass with short refractory period and delayed 
conduction increases the number of wavelets, favouring sustained AF. 
 
 For many years, the multiple wavelet hypotheses were the 
dominant theory explaining the mechanism of AF.     
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Figure 1. The atria contain the heart’s natural pacemaker, the SA node, 
and are the part of the heart affected by atrial fibrillation. The ventricles 
are the muscular part of the heart that actually pumps the blood. They are 
electrically isolated from the atria, and the only way the electrical signal 
can reach them is via the AV node. 
 
 
Figure 2. A, Sinus rhythm. During normal sinus rhythm, the heartbeat is 
a single carefully coordinated process beginning in the SA node (1). The 
electrical signal spreads across the atria (2) and via the AV node (3) to the 
ventricles (4). B, Atrial fibrillation. When patients are in AF, the atria are 
constantly activating in a chaotic 
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Figure 3. Posterior view of principal electrophysiological mechanisms of 
atrial fibrillation. Focal activation. The initiating focus (indicated by the 
star) often lies within the region of the pulmonary veins. The resulting 
wavelets represent fibrillatory conduction, as in multiple-wavelet re-
entry. B, Multiple-wavelet re-entry. Wavelets (indicated by arrows) 
randomly renter tissue previously activated by the same or another 
wavelet. The routes the wavelets travel vary.           
 
ATRIAL ELECTRICAL REMODELING: 
After a period of rapid atrial rate, electrical remodelling of atria 
occurs. Which stimulates progressive intra cellular calcium current in 
terms shortens the action potential duration and atrial refractory period. 
This may promote sustained AF.Described by Phrase. 
     “Atrial fibrillation begets atrial fibrillation” 
    Tachycardia induced AF may result from AV node re-entry, an 
accessory pathway, atrial tachycardia, atrial flutter. 
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II. ATRIOVENTRICULAR CONDUCTION: 
In the absence of accessory pathways or His- purkinge     
dysfunction, the AV node limits conduction during AF multiple atrial 
inputs to the AV node have been identified, two of which seem dominant, 
one directed posteriorly via the christa terminalis and the other aimed 
anteriorly via interatrial septum other factors affecting AV conduction are 
the intrinsic refractoriness of the AV node, concealed conduction, and 
autonomic tone. Concealed conduction which occurs when atrial 
impulses transverse part of the AV node but are not conducted to the 
ventricles and plays a prominent role in determining the ventricular 
response during AF. 
 
 These impulses after AV nodal refractoriness, slowing or blocking 
subsequent atrial impulses, and may explain the irregularity of ventricular 
response during AF. When the atrial rate is relatively slow during AF the 
ventricular rate is tend to rise, conversely a higher atrial rate is associated 
with slow ventricular rate.                 
 
 
Increased parasympathetic and reduced sympathetic tone exert negative 
dromotropic effects on AV nodal conduction, while the opposite is true in                  
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states of decreased parasympathetic and increased sympathetic tone. 
Vagal tone is also enhances the negative chronotropic effects of  
 
as exemplified by slow ventricular rate during sleep but accelerated 
ventricular response during exercise. Digitalis which slows the 
ventricular rate du concealed conduction in the AV node. Fluctuations in 
autonomic tone can produce disparate ventricular response to AF in a 
given patient ring AF predominantly by increasing vagal tone, is more 
effective for controlling heart rate at rest in AF but less effective during 
activity. Wide swings in rate due to variations in autonomic tone may 
create a therapeutic challenge. 
 
III. Aberrant conduction with AF   (Ashman phenomenon) [12] 
The aberrant conduction was likely to complicate atrial flutter and 
fibrillation when a longer cycle was followed by a shorter cycle. 
Aberration produced by long- short sequence is sometimes referred as 
Ashman phenomenon. It is important to keep in mind that this cycle 
sequence cannot be used to differentiate aberration from ectopy because 
by the rate of bigemini, a lengthened cycle also tends to participate a 
ventricular extra systole therefore a long short sequence ending with wide 
QRS complex is as likely to represent a VPB as an aberrant beat. 
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IV: AF with preexcitation: [7, 12] 
 (Atrioventricular conduction in patients with preexcitation) 
Conduction across an accessory pathway during AF can result in a 
dangerously rapid ventricular rate. Whereas a substantial increase in 
sympathetic tone may increase the pre-existed ventricular response. 
Alterations in vagal tone have little effect on conduction over accessory 
pathways. 
 
    Transition of AV re-entry into AF in patients with wolf-
Parkinson-white syndrome can produce a rapid ventricular response 
that degenerates into ventricular fibrillation, leading to death. Intravenous 
administration of drugs such as digitalis, verapamil, diltiazem, which 
lengthen refractoriness and slow conduction across the AV node, does not 
block conduction over the accessory pathway and may accelerate the 
ventricular rate. Hence these agents are contraindicated in this situation. It 
should be treated as emergency usually with DC cardio version. 
 
V.Neurogenic Atrial Fibrillation [14, 15] 
Coumel described a vagal and adrenergic form of AF.  
Vagal origin of AF is characterized by 
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(1) Predominance in men rather than in women (approximately 4:1) 
(2) Age at onset approximately 40 to 50 years 
(3) Lone AF with minimal tendency to permanent AF  
(4) Occurrence at night, during rest, after eating, or with absorption of 
alcohol; and 
(5) AF usually preceded by progressive bradycardia. Importantly, both ß-
adrenergic blocking drugs and digitalis may increase frequency of AF.  
 
Adrenergic AF has the following features: 
(1) Occurs less frequently than vagal AF; 
(2) Onset is exclusively during daytime;  
(3) Often preceded by exercise and emotional stress;  
(4) Polyuria is common;  
(5) Onset typically occurs with a specific sinus rate, often near 90 
beats/min. In contrast to vagally induced AF, ß-adrenergic blockers are 
usually the treatment of choice.  
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Patients with "pure" vagally dependent or adrenergic AF are very 
uncommon. However, history taking may reveal a pattern of onset of AF 
that has elements of one of these syndromes. This is important because it 
allows the clinician to select agents that are more likely to prevent 
episodes of AF in these patients.  
 
 
 
 
 
 
 
 
 
 
 
19 
  
ETIOLOGY OF ATRIAL FIBRILLATION: [6, 7, 13]  
I.CARDIAC 
1.  valvular heart disease (most often mitral valve disease) 
2.  Congestive cardiac failure 
3.  Coronary artery disease 
4.  Hypertension(particularly when LVH is present) 
5.  Hypertrophic cardiomyopathy 
6.  Dilated cardiomyopathy 
7.  Restrictive cardiomyopathy  
(Amyloidosis, Hemochromatosis, Endomyocardial fibrosis) 
8.  Congenital heart disease(ASD, MVP) 
9.  Myocarditis  
10. Pericarditis 
11. Cardiac tumours 
12. WPW syndrome 
13. After CABG  
 (Occurs in up to 40% of patients primarily within 2-3   days) [6] 
14. Calcification of mitral annulus 
15. Idiopathic dilatation of RA 
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II.NON CARDIAC CAUSES: [16, 7, 13] 
1. Thyrotoxicosis 
2. Pheochromocytoma 
3. Respiratory causes 
--Acute and chronic pulmonary disease      
(pneumonia, COPD) 
--pulmonary vascular disease     (pulmonary 
embolism) 
4. Electrolyte disturbances 
Hypokalemia,  
Hypocalcaemia   
Hypomagnesaemia 
5. excessive alcohol intake 
--binge drinking or holiday heart syndrome 
6. increase sympathetic tone 
--exercise, adrenergically mediated arrhythmia 
usually during daytime. 
7. Increase parasympathetic tone 
--Vagally induced and post prandial arrhythmia. 
8. Carbon monoxide poisoning 
9. Hypothermia 
21 
  
10. Duel chamber pacemaker in the presence of normal AV 
conduction. 
11. Caffeine 
12. Smoking 
13. Obesity  
(Graded increase in LA size as BMI increases from 
normal to overweight and obese categories) 1,2,4,5 
III.FAMILIAL: [6, 7, 9, 13] 
                Lone atrial fibrillation. 
      
IV.OTHERS: 
1. Duchene muscular dystrophy [6] 
2. Myotonic dystrophy[6] 
3. The fonton patient[6] 
 (Palliative procedure that redirects the systemic venous return 
directly to the pulmonary arteries without passing through a 
sub pulmonary ventricle useful in tricuspid atresia, hypo 
plastic left heart syndrome, double inlet ventricle) 
4. Electrocution 
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           CLINICAL MANIFESTATIONS: [6, 11] 
 
¾ Palpitations 
¾ Chest pain 
¾ Dyspnoea 
¾ Fatigue 
¾ Light headedness or syncope 
¾ Polyuria( may be associate with the release of atrial 
natriuretic peptide[11]  particularly as episodes of AF begin or 
terminate) 
¾ Features of embolic complication (stroke or TIA) 
¾ Features of exacerbation of heart failure. 
 
PHYSICAL FINDINGS: [6, 8] 
1. Irregular pulse with or without tachycardia, is typically 
described as irregularly irregular rhythm. 
2. Significant pulse deficit. 
3. Variation in intensity of first heart sound. 
4. Absence of ‘a’ wave in JVP. 
5. Hypotension and poor perfusion caused by decrease in atrial 
filling pressures and decrease in stroke volume are common 
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findings. This may be either rate related or because of lack 
of normal atrial kick. 
6. Congestive heart failure, if present may be indicated by 
rales, jugular venous distension, peripheral edema, and 
gallop, which may be difficult to auscultate due to rapid rate. 
7. Signs of embolisation, including TIA, stroke, and peripheral 
arterial embolisation may be indicated. 
 
INVESTIGATIONS: [8, 16] 
 
1. Complete blood count (looking for anaemia, infection) 
2. Blood urea and serum creatinine, electrolytes 
3. Cardiac enzymes—CK and /or troponin level  
        (To investigate myocardial infarction as a primary or secondary 
event) 
4. Thyroid function test. [15] 
5. Digoxin level when appropriate  
 (To look for sub therapeutic level and/ or toxicity). It is generally 
considered safe to administer Digoxin to a patient with AF on 
Digoxin for rare control without waiting for a level to return from 
the laboratory when patient presents with AF. [8] 
6. Toxicology screening [8] 
24 
  
7. ECG –                
 
 
                     
o Absent ‘p’ waves 
o Replace by irregular chaotic fibrillatory ‘F’ waves, in the    
setting of   irregular QRS complexes. 
o Look for aberrantly conducted beats after long – short R-R 
cycles( Ashman phenomenon) 
o Evidence of LVH, preexcitation, bundle branch blocks, acute 
or prior myocardial infarction.  And intervals (R-R, QRS, 
QT) 
 
8. Holter monitoring or event monitoring may be considered for those   
discharged from emergency department.  
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If paroxysmal AF is suspected but the electrocardiogram shows a 
regular rhythm, episodes may be documented with the use of Holter 
monitoring (continuous ECG recording for 24 hours). If the symptoms 
are very infrequent, longer periods of continuous monitoring may be 
required. 
 
9. Exercise testing might also be used in the outpatient setting to 
determine   adequacy of rate-control, to reproduce exercise induced 
AF, and to exclude ischemic pathology. 
 
10. Chest X- ray -- may be normal  
            Radiographic evidence of CHF, RHD, cardiomyopathy, lung or 
vascular pathology.  
                 In particular, if an underlying pneumonia is suggested, and 
then treatment of the pneumonia may cause the atrial fibrillation to 
terminate on its own. 
   11. Echocardiography may be used to evaluate for  
¾ Valvular heart disease 
¾ Right and left atrial size and function. 
¾ LV size and function 
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¾ LVH, RVH 
¾ Pericardial disease 
¾ Vegetations 
¾ thrombus 
       12. Trans oesophageal echocardiography— 
                        High sensitivity in detecting LA thrombus. 
 
 
 
DIFFERENTIAL DIAGNOSIS: 
1. Atrial extra systole 
2. Atrial tachycardia( multifocal) 
3. Atrial flutter 
4. WPW syndrome 
 
COMPLICATION: 
1. Stroke 
2. Tachycardia induced cardiomyopathy 
3. Heart failure  
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TREATMENT: 
                 The main goals of treatment of atrial fibrillation are to prevent 
temporary circulatory instability and to prevent stroke. Rate and rhythm 
control are principally used to achieve the former, while anticoagulation 
may be required to decrease the risk of the latter. In emergencies, when 
circulatory collapse is imminent due to uncontrolled tachycardia, 
immediate cardioversion may be indicated. [18] 
The primary factors determining atrial fibrillation treatment are 
duration and evidence of hemodynamic instability. Cardioversion is 
indicated with new onset AF (for less than 48 hours) and with 
hemodynamic instability. If rate and rhythm control can not be 
maintained by medication or cardioversion, electrophysiological studies 
with pathway ablation may be required. [18] 
Prehospital Care [8] 
• Care of hemodynamically unstable patients is guided by ACLS 
protocols, including direct current (DC) cardio version.  
• Symptomatic patients may benefit from intravenous (IV) rate-
controlling agents, either calcium-channel blockers or beta-
adrenergic blockers. 
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Emergency Department Care [8] 
The immediate role of the emergency medicine physician is to 
ascertain and ensure hemodynamic stability. Once this is done, the 
approach to atrial fibrillation is facilitated by generally accepted 
protocols. 
• Urgently assess need for interventions, including the following:  
o Airway and oxygenation (pulse oximetry); O2 supplementation as 
needed  
o Blood pressure support (often difficult until rate is controlled)  
o A patient with hemodynamic instability, mental status changes, 
preexcitation, or angina will require urgent synchronized DC 
cardio version.  
  Obtain emergent laboratory and imaging studies (ECG, chest 
radiography).   
 Once the patient has been determined to be hemodynamically 
stable, often the first step to control ventricular tachycardia is 
the administration of a rate-controlling agent (a beta-blocker or 
a calcium-channel blocker). In a small percentage of cases, the 
patient may revert to sinus in response to a slowing down of the 
rate.  
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 If the patient persists in AF, anticoagulation should be initiated 
with either intravenous or subcutaneous heparin. The treatment 
branch then divides patients into duration of AF. Patients with 
duration of less than or equal to 48 hours (and without 
significant LV dysfunction, mitral valve disease, or prior 
embolism) may undergo immediate pharmacologic or DC 
cardio version. AF of duration of greater than 48 hours, or 
unknown duration, or high risk of embolisation can either 
undergo TEE-guided DC cardio version or be anticoagulant for 
3 weeks, followed by DC cardio version. Multiple studies have 
shown the safety/efficacy of TEE-facilitated early cardio 
version versus conventional therapy. Although patients who 
have been on anticoagulation already for at least 3 weeks can be 
cardioverted without TEE, if any complicating factor (e.g., 
valvular disease, LV dysfunction) is present, TEE should be 
considered. 
 Methods of cardio version: Cardio version may be achieved by 
means of drugs or electrical shocks. Electrical cardioversion is 
more effective than pharmacologic cardioversion, though it 
requires sedation/anesthesia.  
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ELECTRICAL CARDIOVERSION  
 Direct-current cardio version involves an electrical shock 
synchronized with the intrinsic activity of the heart to ensure 
that electrical stimulation does not occur during the vulnerable 
phase of the cardiac cycle. The success rate of DC cardio 
version is 75-93%, with efficacy positively correlating to energy 
setting (360>200>100 J), and negatively correlating with 
duration of AF and left atrial size.  
 Paddle positions include anterior-lateral (ventricular apex and 
right infraclavicular) and anterior-posterior (sternum and left 
scapular), with at least one study suggesting increased efficacy 
with the anterior-posterior method.  
 Cardio version of patients with implanted pacemakers and 
defibrillator devices is safe when appropriate precautions are 
taken. Risks of electrical cardio version include embolic events 
and cardiac arrhythmias. Transient ST-segment elevations can 
be present after cardio version, as well as a bump in cardiac 
enzyme levels without apparent myocardial damage.  
 The relapse rate after initial successful cardioversion is high: 
25%-50% at 1 month and 70%-90% at 1 year.  
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 While successful cardioversion in AF of duration greater than 
48 hours will require 6-12 weeks of anticoagulation due to atrial 
stunning, no clear consensus exists for anticoagulation after 
cardioversion for AF of less than 48 hours. One approach is to 
divide these patients into low-risk (treat with aspirin) and 
higher-risk (traditional anticoagulation). 
PHARMACOLOGIC CARDIOVERSION  
 Pharmacologic cardioversion appears to be most effective when 
initiated within 7 days after the onset of AF. .  
 The risk factors for pharmacologic cardioversion include Brady 
arrhythmia, QT prolongation, and ventricular arrhythmias. 
 
  A study by Michael et al looked at 289 patients seen during an 18-
month period in an emergency department setting. Sixty-two percent 
(180) underwent attempted chemical cardioversion with a 50% success 
rate, and 28% (80) had attempted electrical cardioversion with a 89% 
success rate. Ninety-three percent of electrical cardioversions were 
performed by emergency physicians. They concluded that cardioversion 
and immediate discharge of patients who present to the ED with acute 
atrial fibrillation appears to be both safe and effective.  
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Reasons for hospitalization would include but not be limited to the 
following:  
 Presence of co morbidities  
 For workup or treatment of underlying aetiology of AF, 
including evaluation for ACS or myocardial infarction  
 For elderly patients  
 For patients with underlying heart disease  
 Patients at risk of complications from AF therapies 
 
CONSULTATIONS [8] 
• Patients with AF who are treated in the ED generally require 
consultation with a cardiologist. Those with new-onset AF and 
those with associated symptoms related to rate are generally 
admitted to rule out MI and to evaluate for possible elective 
cardioversion.  
• A patient's cardiologist plays a vital role in determining the most 
appropriate long-term strategy for a patient with AF and provides 
crucial follow-up.  
• A cardiologist may become involved emergently if complicating 
factors are present or if the patient is experiencing ongoing cardiac 
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ischemia or infarction not treatable with rate reduction measures 
and standard chest pain protocols. A patient with AMI and new-
onset AF who is stable may benefit from simple [8, 16]e rate-control 
measures (e.g., intravenous beta-blockers, intravenous magnesium 
sulphate 2 g over 10 min) while being prepared for the 
catheterization laboratory and intravenous nitrates, heparin, and 
aspirin are begun.  
MEDICATION: 
Pharmacologic agents in AF fall into 1 of 2 classes: rate-
controlling drugs and rhythm restoring/rhythm maintenance drugs 
(though some overlap exists with some drugs, such as amiodarone, 
exhibiting both qualities).  
RATE-CONTROLLING DRUGS 
In patients without ventricular preexcitation, rate is controlled most 
effectively with intravenous verapamil, diltiazem, or beta-adrenergic 
blockers. Beta-blockers are especially effective in the presence of 
Thyrotoxicosis and increased sympathetic tone or in patients with 
myocardial ischemia/AMI. The non-hydro pyridine calcium channel 
blockers may be chosen in patients lacking any history of heart failure 
and in patients with reactive airway disease. 
34 
  
Anecdotally, intravenous diltiazem has become many emergency 
medicine physicians’ first-line rate-controlling drug in patients without a 
history of heart failure. 
Digoxin is ineffective in controlling ventricular rate during acute 
episodes. 
In patients with acute or chronic heart failure, Digoxin or 
amiodarone should be used. (Amiodarone does not currently have FDA 
approval for this intervention.) 
ANTIARRHYTHMIC DRUGS 
Antiarrhythmic drugs that can terminate AF include procainamide, 
disopyramide, propafenone, sotalol, flecainide, amiodarone, and ibutilide. 
The efficacy of antiarrhythmic drugs has been linked to the duration of 
AF. 
The American College of Cardiology/American Heart 
Association / European Society of Cardiology (ACC/AHA/ESC) 
Guidelines make the following recommendations regarding 
pharmacologic conversion of AF: 
•  
•  
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• conversion of AF less than or equal to 7 days  
o Agents with proven efficacy include dofetilide, flecainide, 
ibutilide, propafenone, and to a lesser degree, amiodarone 
and quinidine.  
o Less effective or incompletely studied agents in this scenario 
include procainamide, digoxin, and sotalol. 
 
• Conversion of AF lasting greater than 7 days  
o Agents with proven efficacy include dofetilide, amiodarone, 
ibutilide, flecainide, propafenone, and quinidine.  
o Less effective or incompletely studied agents in this scenario 
include procainamide, sotalol, and digoxin. 
• Conversion of AF lasting greater 90 days - Oral propafenone, 
amiodarone, and dofetilide have been shown to be effective at 
converting chronic AF to normal sinus rhythm (NSR). 
A newer agent and recently approved class III antiarrhythmic is 
dofetilide. Another drug, azimilide, has been studied in the recent 
Azimilide Post-Infarct Survival Evaluation (ALIVE) trial, a post–heart 
attack survival study. Additional data from ALIVE further support the 
ongoing development of azimilide as a treatment for supraventricular 
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arrhythmias. Fewer patients in sinus rhythm at baseline developed 
AF/atrial flutter during the trial on azimilide compared with placebo. 
Another newer drug is dronedarone, a deiodinated derivative of 
amiodarone that has no organ toxicity. Its use extends to atrial and 
ventricular arrhythmias. At present, dronedarone is an experimental agent 
that has multiple actions (all 4 Von Williams class effects). Unlike 
amiodarone, it does not have the iodine moiety. The lack of iodination 
may offer a better adverse-effect profile. Dronedarone has been shown to 
(1) have antiadrenergic effects 
(2) Prolong atrial and ventricular refractory periods, and 
(3) prolong atrioventricular node conduction and the paced QRS 
complex. 
In animal models, dronedarone has been shown to decrease 
ischemia-induced ventricular arrhythmias. The clinical effects of 
dronedarone are now being examined in patients with AF and in patients 
with internal cardioverter-defibrillators (ICDs).  
When considering drug therapy for AF, remember the treatment 
caveat: "Electrical cardioversion is the preferred modality in the patient 
whose condition is unstable." 
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ANTICOAGULATION[25 ,26,27,28,29,30,31,32] 
Patients with atrial fibrillation, even lone atrial fibrillation without 
other evidence of heart disease, are at increased risk of stroke during long 
term follow up. A systematic review of risk factors for stroke in patients 
with nonvalvular atrial fibrillation concluded that a prior history of stroke 
or TIA is the most powerful risk factor for future stroke, followed by 
advancing age, hypertension, and diabetes. The risk of stroke increases 
whether the lone atrial fibrillation was an isolated episode, recurrent, or 
chronic. The risk of systemic embolization (atrial clots migrating to other 
organs) depends strongly on whether there is an underlying structural 
problem with the heart (e.g. mitral stenosis) and on the presence of other 
risk factors, such as diabetes and high blood pressure. Finally, patients 
under 65 are much less likely to develop embolization compared with 
patients over 75. In young patients with few risk factors and no structural 
heart defect, the benefits of anticoagulation may be outweighed by the 
risks of hemorrhage (bleeding). Those at a low risk may benefit from 
mild (and low-risk) anticoagulation with aspirin (or clopidogrel in those 
who are allergic to aspirin). In contrast, those with a high risk of stroke 
derive most benefit from anticoagulant treatment with warfarin or similar 
drugs. 
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In the United Kingdom, the NICE guidelines recommend using a 
clinical prediction rule for this purpose.  The CHADS/CHADS2 score is 
the best validated clinical prediction rule for determining risk of stroke 
(and therefore who should be anticoagulated); it assigns points (totaling 
0-6) depending on the presence or absence of co-morbidities such 
hypertension and diabetes. In a comparison of seven prediction rules, the 
best rules were the CHADS2 which performed similarly to the SPAF and 
Framingham [15] prediction rules.  To compensate for the increased risk of 
stroke, anticoagulants may be required. However, in the case of warfarin, 
if a patient has a yearly risk of stroke that is less than 2%, then the risks 
associated with taking warfarin outweigh the risk of getting a stroke.  
ACUTE ANTICOAGULATION 
If anticoagulation is required urgently (e.g. for cardioversion), 
heparin or similar drugs achieve the required level of protection much 
quicker than warfarin, which may take several days to reach adequate 
levels.  
In the initial stages after an embolic stroke, anticoagulation may be 
risky, as the damaged area of the brain is relatively prone to bleeding 
(hemorrhagic transformation). As a result, a clinical practice guideline by 
National Institute for Health and Clinical Excellence recommends that 
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anticoagulation should begin two weeks after stroke if no hemorrhage 
occurred.  
CHRONIC ANTICOAGUATION 
Among patients with "non-valvular" atrial fibrillation, 
anticoagulation can reduce stroke by 60% while antiplatelet agents can 
reduce stroke by 20%. There is evidence that aspirin and clopidogrel are 
effective when used together, but the combination is still inferior to 
warfarin.  
Warfarin treatment requires frequent monitoring with a blood test 
called the international normalized ratio (INR); this determines whether 
the correct dose is being used. In atrial fibrillation, the usual target INR is 
between 2.0 and 3.0 (higher targets are used in patients with mechanical 
artificial heart valves, many of whom may also have atrial fibrillation). A 
high INR may indicate increased bleeding risk, while a low INR would 
indicate that there is insufficient protection from stroke. 
ELDERLY PATIENTS 
The very elderly (patients aged 75 years or more) may benefit from 
anticoagulation provided that their anticoaguation does not increase 
hemorrhagic complications, which is a difficult goal. Patients aged 80 
years or more may be especially susceptible to bleeding complications, 
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with a rate of 13 bleeds per 100 person-years. A rate of 13 bleeds per 100 
person years would seem to preclude use of warfarin; however, a 
randomized controlled trial found benefit in treating patients 75 years or 
over with a number needed to treat of 50. Of note, this study had very low 
rate of hemorrhagic complications in the warfarin group. 
RATE CONTROL VERSUS RHYTHM CONTROL 
AF can cause disabling and annoying symptoms. Palpitations, 
angina, lassitude (weariness), and decreased exercise tolerance are related 
to rapid heart rate and inefficient cardiac output caused by AF. 
Furthermore, AF with a persistent rapid rate can cause a form of heart 
failure called tachycardia induced cardiomyopathy. This can significantly 
increase mortality and morbidity, which can be prevented by early and 
adequate treatment of the AF. 
There are two ways to approach these symptoms: rate control and 
rhythm control. Rate control treatments seek to reduce the heart rate to 
normal, usually 60 to 100 beats per minute. Rhythm control seeks to 
restore the normal heart rhythm, called normal sinus rhythm. Studies 
suggest that rhythm control is mainly a concern in newly diagnosed AF, 
while rate control is more important in the chronic phase. Rate control 
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with anticoagulation is as effective a treatment as rhythm control in long 
term mortality studies, the AFFIRM Trial.  
The AFFIRM study showed no difference in risk of stroke in 
patients who have converted to a normal rhythm with anti-arrhythmic 
treatment, compared to those who have only rate control. 
RATE CONTROL 
Rate control is achieved with medications that work by increasing 
the degree of block at the level of the AV node, effectively decreasing the 
number of impulses that conduct down into the ventricles. This can be 
done with:  
• Beta blockers (preferably the "cardioselective" beta blockers such 
as metoprolol, atenolol, bisoprolol)  
• Cardiac glycosides (i.e. digoxin)  
• Calcium channel blockers (i.e. diltiazem or verapamil)  
In addition to these agents, amiodarone has some AV node 
blocking effects (particularly when administered intravenously), and can 
be used in individuals when other agents are contraindicated or 
ineffective (particularly due to hypotension). 
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CARDIOVERSION 
Rhythm control methods include electrical and chemical 
cardioversion:  
• Electrical cardioversion involves the restoration of normal heart 
rhythm through the application of a DC electrical shock.  
• Chemical cardioversion is performed with drugs, such as 
amiodarone, dronedarone[26], procainamide, ibutilide, propafenone 
or flecainide.  
The main risk of cardioversion is systemic embolization of a 
thrombus (blood clot) from the previously fibrillating left atrium. 
Cardioversion should not be performed without adequate anticoagulation 
in patients with more than 48 hours of atrial fibrillation. Cardioversion 
may be performed in instances of AF lasting more than 48 hours if a 
transesophogeal echocardiogram (TEE) demonstrates no evidence of clot 
within the he.  
New understanding of the mechanism of atrial fibrillation 
While it was once thought that atrial fibrillation was initiated by 
areas of electrical activity (foci) located all over the atria, research by 
Haissaguerre and co-workers proved that the majority of irregular foci 
(94%) come from the areas around the four pulmonary veins. Other less 
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common areas include the superior vena cava, right and left atrium, and 
the coronary sinus. This information has led to new ablation and surgical 
techniques to treat atrial fibrillation, including pulmonary vein ablation. 
PULMONARY VEIN ISOLATION ABLATION 
Ablation of the four pulmonary veins, using a circumferential 
mapping technique, is proving to be successful for many patients with 
atrial fibrillation.  
The procedure involves the use of special catheters (soft wires) 
inserted into the left atrium. The catheters are used for mapping 
(searching for the electrical impulses that fire abnormally, causing atrial 
fibrillation) and the delivery of energy (ablation) to the area. Energy is 
delivered from one catheter into the area of the atria that connects to the 
pulmonary vein, producing a circular scar. The scar will then block any 
impulses firing from within the pulmonary vein, thus preventing atrial 
fibrillation from occurring. The process is repeated to all pulmonary 
veins.  
Dr. Andrea Natale, department of Cardiovascular Medicine, 
section of Electrophysiology and Pacing, says, "This procedure has an 
80% success rate with the first ablation. For those who have returned for 
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further ablation, the success rate has been 95%. After a period of recovery 
following the procedure, most patients can stop taking blood thinners." 
Dr. Natale is investigating other methods of pulmonary vein 
ablation. The goal is to isolate the energy delivered to the ostium 
(opening) of the pulmonary veins. Circumferential Ultrasound Vein 
Ablation (CUVA) involves using a circular ultrasound catheter inserted 
into the pulmonary veins and delivering energy around the pulmonary 
vein ostium. Although this appeared promising, initial studies showed a 
high rate of pulmonary vein stenosis (narrowing) occurred. Future 
research is aimed at improving this technique. 
SURGICAL PROCEDURES 
Several factors have contributed to surgical approaches to treat 
atrial fibrillation: 
• atrial fibrillation is very common and those with atrial fibrillation 
often have concurrent heart disease (coronary artery disease or 
valve disease) requiring surgery  
• all patients with atrial fibrillation are not treatable by non-surgical 
methods  
• new energy sources are available, increasing the safety and success 
rate  
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The Maze procedure (Cox-Maze procedure), developed by Dr. 
Jim Cox, began the surgical approach to treatment of atrial fibrillation. 
The surgery involves creating precise incisions in the right and left atria 
to interrupt the conduction of abnormal impulses and to direct normal 
sinus impulses to travel to the atrioventricular node (AV node) as they 
normally should. The Maze procedure has been very successful with a 95 
% success rate. A number of surgeons have altered the traditional Cox-
Maze procedure to focus mainly on the left atrium.  
The success of the modified Maze procedures has supported the 
notion that the isolation of the pulmonary veins and portions of the left 
atrium can eliminate atrial fibrillation. This has encouraged surgeons to 
seek out other methods of isolation rather than cutting and sewing. Three 
alternative energy sources have been used surgically to treat atrial 
fibrillation: radiofrequency, microwave and cryothermy. The goal of all 
three is to produce lesions and ultimately scar tissue to block the 
abnormal electrical impulses from being conducted through the heart and 
promote the normal conduction of impulses through the proper pathway. 
Radiofrequency ablation uses radiofrequency energy to heat the 
tissue and produce lesions on the heart, eliminating the incisions 
necessary in the Maze procedure. There is a variety of surgical techniques 
related to the type of catheter used, the dose of energy, and the types of 
46 
  
lesions created. Radiofrequency surgical ablation has proved to be 
successful in 80 % of cases. The greatest risk of this procedure is damage 
to surrounding structures, such as the oesophagus. 
Cryothermy (also called cryoablation) uses very cold 
temperatures through a probe (called a cryoprobe) to create lesions. This 
technique is used commonly during arrhythmia surgery to replace the 
incisions made during the Cox-Maze procedure. This technique cures 
atrial fibrillation in close to 80% of people. 
Microwave technology uses a special catheter (the Flex-4 
catheter) to direct microwave energy to create several lesions on the 
heart. The lesions block the conduction of abnormal electrical beats and 
restore a normal heartbeat. The benefit of microwave radiation in 
comparison to other surgical ablation techniques, is that the depth and 
volume of heated tissue is more controlled and precise lesions are created, 
and less charring of the heart's surface occurs, decreasing the risk of 
blood clots that may travel to the brain or other organs. Microwave 
energy cures atrial fibrillation in about 80 % of people.  
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MORTALITY/MORBIDITY 
• The rate of ischemic stroke among patients with nonrheumatic AF 
averages 5% a year, which is somewhere between 2-7 times the 
rate of stroke in patients without AF. The risk of stroke is not due 
solely to AF; it increases substantially in the presence of other 
cardiovascular disease.  
• The attributable risk of stroke from AF is estimated to be 1.5% for 
those aged 50-59 years, and it approaches 30% for those aged 80-
89 years.  
• The total mortality rate is approximately doubled in patients with 
AF compared with patients in normal sinus rhythm and is linked 
with the severity of underlying heart disease.  
• AF complicates acute myocardial infarction (AMI) in 5-10% of 
cases. The causes of AF in AMI are thought to be due to any 
number of factors, such as atrial infarction, atrial ischemic injury, 
atrial distension, or, perhaps, Pericarditis. According to Rathore et 
al, patients who developed new-onset AF during the course of 
myocardial infarction (MI) were at higher risk than patients who 
presented with chronic AF. Patients with AMI and AF tend to be 
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older, be less healthy, and have poorer outcomes during 
hospitalization and after discharge than individuals without AF. AF 
is independently associated with an increased mortality rate. 
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MATERIALS AND METHODS 
 
 
  
 
MATERIALS AND METHODS 
 
This study was conducted at Coimbatore medical college hospital, 
Coimbatore. This study was conducted during period of Jan 2006 to June 
2007, 50 cases with atrial fibrillation were included in this study.50 
consecutive cases were recorded. No patients had been counted twice if 
he or she got admitted again after discharge during this period. 
 
Inclusion Criteria   
 
Both male and female patients were included in this study.  
Samples were collected from medical OP, medical ward, ICCU, 
cardiology OP.  
 
Exclusion Criteria  
Paediatric patients were not included in this study. 
 
THE DIAGNOSIS OF AF: 
 
The diagnosis was made on clinical grounds and then confirmed by 
ECC and Echo cardiogram. 
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Clinical Features: 
The following symptoms were enquired from all the patients. 
Those include dyspnoea, palpitation, chest pain, fatigue, dizziness, 
neurological deficit, oliguria. 
 
The presence of following signs was made out. That includes pedal 
edema, puffiness of face, cyanosis, anaemia, signs of hyperthyroidism. 
Heart rate, pulse rate, pulse deficit, blood pressure monitoring, 
JVP-absent “a” wave, cardio vascular system examination were 
documented in all the patients. 
 
ECG RECORDING: 
 
            A, 12, lead ECC was taken for all the cases. It was standardized to 
produce a deflection of 10 mm per 1MV input and the paper speed was 
set at 25 mm per second. The ECC features of AF were noted, it includes  
• Absent P wave 
• Replaced by irregular chaotic fibrillatory F waves, in the setting of 
irregular QRS complex.  
• Look for LVH, free excitation, bundle branch blocks, acute or prior 
myocardial infarction  
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ECHOCARDIOGRAPHY: 
9 M-mode, 2D echo was done in all the patients.  
9 The rhythm of heart was noted. 
9 The presence of valve thickening and calcification and 
regurgitation were noted.  
9 Size of valve orifice and chambers of heart were assessed.  
9 Presence of clot in the atrium and atrium appendages was 
identified.  
9 Vegetations were searched. 
9  Ejection fraction of ventricle was measured.  
FEATURES ACCORDING TO SUSPECTED ETIOLOGY: 
1. Rheumatic heart disease: 
• Features of rheumatic fever ( as per updated Jones criteria) 
• Features of heart failure ( as per Framingham criteria) 
• The presence of valvular  heart disease 
• Features of infective endocarditis  
• Serum ASO titre, ESR, CRP  
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• 
X-ray chest PA view ( chamber hypertro phy, cardiomegaly, 
mitralisation of heart ) 
  
 
X-RAY SHOWS STRAIGHTENING OF LEFT BORDER OF 
HEART IN MITRAL STENOSIS 
 
 
 
 
X-RAY SHOWS LEFT ATRIAL ENLARGEMENT IN A 
CASE OF MITRAL STENOSIS WITH REGURGITATION 
 
  
 
 
 
 
 
X-RAY SHOWS ISCHEMIC CARDIOMYOPATHY 
 
 
 
X-RAY OF ATRIAL SEPTAL DEFECT [JUG HANDLE 
APPEARANCE] 
  
 
 
 
ECHO CARDIOGRAPHY OF RHD PATIENT[MS+MR] 
SHOWS LARGE CLOT 
 
 
 
 
 
  
2. Coronary artery hypertensive disease: 
• History 
• Peripheral arterial thickening  
• Auscultation for S3,S4 (Which may denotes compliance of 
ventricle) 
• Fundus examination  
3.    Hypertensive heart disease 
• BP monitoring 
• Fundus examination  
• Urine analysis 
• Blood urea and creatinine level 
• If necessary other investigation to find out whether 
hypertension is primary or secondary  
4.    Chronic obstructive air way disease 
• History related to chronic lung disease 
• Chest wall deformities 
• Cardiac auscultation to find out pulmonary hypertension, 
pulmonary regurgitation, tricuspid regurgitation  
• ECC – P- pulmonale, RVH, RBBB, X- old PT, fibrosis, 
emphysematous chest, Bronchectasis  
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DATA ANALYSIS  
  
AETIOLOGY 
62%
8%
8%
12%
6%
4%
Rheumatic Heart Diseases 
Congenital heart Disease 
Ischemic Heart Disease
Hypertensive Heart Disease 
Dilated Cardio myopathy
Corpulmonale 
AETIOLOGY: 
 
 
CAUSES NO.OF  CASES PERCENTAGE 
Rheumatic Heart Diseases  31 62 
Congenital heart Disease  4 8 
Ischemic Heart Disease 4 8 
Hypertensive Heart Disease  6 12 
Dilated Cardio myopathy 3 6 
Corpulmonale  2 4 
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AGE DISTRIBUTION: 
 
 
AGE IN YEARS NO.OF  CASES PERCENTAGE 
13 -20 1 2 
21 – 30 7 14 
31- 40 10 20 
41 -50 15 30 
51-60 6 12 
61 and above 11 22 
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GENDER DISTRIBUTION 
 
 
CAUSES MALE FEMALE 
Rheumatic Heart Diseases  12 19 
Congenital heart Disease  1 3 
Ischemic Heart Disease 3 1 
Hypertensive Heart Disease  3 3 
Dilated Cardio myopathy 1 2 
Corpulmonale  1 1 
Total 21 29 
Percentage % 42 58 
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TYPES OF VALVULAR LESION IN  
RHEUMATIC HEART DISEASE 
 
 
Types of valvular 
lesions 
Number of cases Percentage 
Mitral stenosis(MS) 9 29 
Mitral 
Regurgitation(MR) 
0 0 
MS+MR 13 41 
MS+MR+AS 2 7 
MS+MR+AR 4 13 
MS+MR+AS+AR 3 10 
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PREVIOUS HISTORY OF RHEUMATIC FEVER 
 
No Of Cases Of RHD
 
History Of 
Rheumatic  fever 
Percentage 
31 13 42 
  
 
SYMPTOM ANALYSIS 
 
SYMPTOMS NUMBER OF 
CASES 
PERCENTAGE 
DYSPNOEA 45 90 
PALPITATION 43 86 
CHEST PAIN 27 54 
FATIGUE 19 38 
DIZZINESS 20 40 
 
 
 
Symptom Analysis
29%
28%
18%
12%
13%
Dyspnoea
palpitation
Chest pain
Fatigue
Dizziness
 
 
 
 
 
 
 
 
 
 
 
58 
  
 
COMPLICATIONS 
 
Complication 
 
Number of cases Percentage (%) 
Heart failure 16 32 
CVA 2 4 
LA clot 3 6 
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DISCUSSION 
An attempt has been made to study fifty cases of AF regarding 
aetiology, clinical manifestations, and complications. 
AGE INCIDENCE: 
In this study of atrial fibrillation cases, the occurrence of AF is 
maximum in age group 41-50 yrs. The incidence is about 30%. The next 
commonly affected age group is elderly people of 61yrs and above. The 
incidence is around 22%. 
According to American heart association the cross sectional studies 
have found low prevalence in those below the age of 65yrs and, 
increasing to 8% in those older than 80 yrs. 
According to AG shaper, HSR Huts zfezfar when 2 series of 
patients with AF were analysed they found mean age of patients seen in 
johanesberg was 38 yrs, where as in London it was 62 yrs. 
The mean prevalence of AF of 0.5% for the group aged 50-59 
years and rises to 8.8% in the group aged 80-89 years. 
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GENDER INCIDENCE: 
  Out of 50 cases 28 cases were female, 22 cases were male, the 
incidence in female is about 58% and incidence in male is about 42%. 
The incidence of familial form of AF is unknown recent studies 
from department of health and human service- USA govt suggest that up 
to 30 % of all people with AF may have history of similar condition in 
their family. 
According to Kannel.WB, AbbotR.D, savage, Mc.namara  
PM. epidemiologic features of chronic AF, The Framingham study 
N.Eng. J. Med 1982; 306; 1088-1122. 
The prevalence of AF increases with age, and slightly more 
common in men than in women. 
The incidence of development of AF over 22yrs in Framingham 
study was 2.2% in man and 1.7 in women. 
AETIOLOGICAL ANALYSIS: 
  In the etiological analysis among 50 cases of AF, the most 
common aetiology was rheumatic heart disease, followed by 
Hypertensive heart disease, ischemic heart disease, congenital heart 
disease, DCM, corpulmonale. 
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RHEUMATIC HEART DISEASE: 
  Out of 50 cases 31 cases were Rheumatic heart disease. Incidence 
of RHD- 62% 
R.Arora, G. Subramanian, M.Khalilullah and M.P Gupta from 
India reported the high incidence of RHD in India. 
AG. Shaper, HSR Hutt, Zfejfar reported that the high incidence of 
RHD is common in tropical countries. 
In western countries, coronary heart disease and hypertensive heart 
disease is common cause of AF than RHD. 
A study was conducted in Govt medical college /Amrister Jan 2007 
66 cases of AF analysed; they reported that RHD was the most common 
cause.  
In this study of 50 cases of AF 31 cases were of rheumatic 
aetiology. In this group of 31 cases 42% of cases were presented with 
previous history of rheumatic fever. This study correlates well with many 
Indian studies. So the incidence of Rheumatic fever is still common in 
India.  
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In these 31 cases of RHD most of the cases were in age group 
between 31-50 years. Most commonly presented with valvular MS + MR, 
followed by Isolated MS.  
According to R. arora, g. Subramanian M. Khaliullah and MG 
Gupta, in their study of 2500 cases of rheumatic heart disease 384 cases 
had atrial fibrillation. Among the AF cases the valvular lesion incident 
was MS 38%, MS + MR 30%.  
The present study shows combination of MS + MR was the most 
common lesion.      
HYPERTENSIVE HEART DISEASE: 
In this study, the SHT with AF is detected 6 cases and incidence 
was 12% 
According to Framingham study, hypertension accounted for about 
half of cases.   
ISCHEMIC HEART DISEASE: 
In this study old myocardial infarction was found in 4 cases. The 
incidence was  8%. 
63 
  
According to Greson VH lip, D. Gracth Beevas. AF may 
complicate Acute MI in 10-155% of cases. But in this study evidence of 
old MI was found in 8% of cases. 
According to Krama RJ, Zelderson, hamby RJ of 1176 patients 
with coronary artery disease 10% had AF. This correlates well with the 
present study. 
CONGENITAL HEART DISEASE: 
In this study out of 50 cases of AF 4 cases were ASD, incidence 
was about 8%. Out of these 4 cases of ASD, 3 cases were in age group 
above 60 yrs.   
DILATED CARDIOMYOPATHY: 
In this study of 50 cases of AF, DCM found in 3 patients. 
Incidence was about 6%. Clinically, echocardiographically and ECG wise 
they had cardiomegaly without valvular lesion and ischemia.  
According to Gurpal singh, Prem arora study of 66 patients of AF, 
they found 15 cases of DCM the incidence were 10.5% . 
 
10-15% 
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CORPULMONALE: 
Out of 50 cases of 2 cases had features of COPD, incidence is 
about 4%. 
SYMPTOM ANALYSIS: 
In symptom analysis dyspnoea and palpitation were the most 
frequent symptoms found in almost all the patients, chest pain is the next 
frequent symptom found in 54% of cases, syncope found in 40% of cases. 
The most frequent symptomatic presentation in this study is dyspnea and 
palpitation. This study correlates well with common symptomatic 
presentation of AF. 
COMPLICATIONS: 
In this analysis atrial fibrillation cases, the most common 
complication documented is heart failure. The percentage is 36%, LA clot 
is found in 6% cases. Cerebro vascular accident is found in 4% of cases.  
                                                                                                    
According to O.T. Samani and HB Chandalia congestive cardiac failure 
was percent in 64 % of cases with atrial fibrillation. 
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Cabin HS, Club KS, Hall C, pertmutter RA, had reported cerebral 
embolism in 85% of cases and peripheral embolism in 15% cases.  
 
In this study pulmonary hypertension is found in 44 % cases. This 
is made out by clinical examination and echocardiography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
• The occurrence of atrial fibrillation was more common above the 
age of 40 years. 
• AF was more common in females – 58% 
• The incidence of AF in men increases with age. 
• In this fifty cases the common aetiology of AF was RHD 62% 
followed by Hypertensive heart disease – 12 %, congenital heart 
disease (ASD) and Ischemic heart disease each carries 8%. 
• In this 62% of rheumatic heart disease with atrial fibrillation. The 
mitral valve was involved in almost all the patients. The 
commonest clinical presentation was MS + MR – 41 %. Followed 
by isolated MS – 29 %. The combination of mitral and aortic valve 
lesion – 10%. 
• The congenital heart disease (ASD) with AF was found in 8% of 
cases.  
• The most common symptomatic presentations were dyspnoea and 
palpitation followed by chest pain and dizziness.  
• The previous history of rheumatic fever was found in 42 % of 
cases.  
• The commonest complication was noted in AF cases was heart 
failure – 32%. CVA with embolic stroke was found in 4% of cases.  
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• Left atrial clot was demonstrated by echo cardio graphically in 6% 
of cases.  
• The pulmonary hypertension was found in 44 % of cases.  
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PROFORMA 
ANALYSIS OF AETIOLOGY CLINICAL FEATURES AND 
COMPLICATIONS OF ATRIAL FIBRILLATION 
 
 
Name:                                      Age:       Sex:         Address: 
 
                Symptoms                     Signs 
Dyspnoea Pedal edema 
Palpitation Puffiness of face 
Chest-pain Cyanosis 
Fatigue Anemia 
Dizziness Signs of hyperthyroidism 
Neurological deficit Other signs 
Oliguria  
 
 
Heart Rate Pulse Rate Pulse 
Deficit 
BP JVP Carotid 
      
 
 
 
CVS Respiratory system 
 
 
Central nervous system 
 
 
 
Abdomen 
 
 
 
 
Investigations: 
Hb% -                                        CPK-MB -                               X-ray chest – 
 
ESR -                                         Trop-T -                                   ECG - 
 
ASO Titre -                                T3 –  
 
Blood Urea -                              T4 – 
 
Blood sugar -                             TSH -                                       ECHO – 
 
 
 
Diagnosis:                                                                                  Complications:          
